Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Codexis, Inc.NASDAQ: CDXS
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital turns negative
Q1 FY2026 change in working capital was -$8.23M, compared with $2.77M a year earlier. Trailing-twelve-month change in working capital was -$4.58M. Over 3 fiscal years it compounded at -33.2% a year.
Context
- Change in working capital amounted to 9.1% of revenue in FY2025, down 11.1 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly change in working capital holds near -$8.23M or moves back toward the trailing-twelve-month quarterly average of -$1.15M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- 6.42M USD
- Year-over-year change
- +153.4%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.42M | +153.4% |
| FY2024 | 2024-12-31 | (12.02M) | +34.0% |
| FY2023 | 2023-12-31 | (18.22M) | -184.4% |
| FY2022 | 2022-12-31 | 21.57M | +382.9% |
| FY2021 | 2021-12-31 | (7.62M) | — |
Change in Working Capital vs competitors
How CDXS compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -40.8% is the 7th highest of 10, against a peer median of -22.8%.
- Change in working capital amounts to 5.9% of revenue for CDXS, versus a peer median of 47.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.74M USD | +149.1% | +20.4% | 68.1% | |
| LTM Mar 2026 | $14.87M USD | -22.8% | +6.9% | 26.6% | |
| FY2025 | €10.21M EUR | -126.1% | -6.5% | 366.4% | |
| LTM Mar 2026 | $7.29M USD | -27.6% | -23.0% | 25.2% | |
| LTM Mar 2026 | $5.97M USD | +455.6% | +139.1% | 188.4% | |
| LTM Mar 2026 | $5.7M USD | -57.2% | -62.8% | 16.5% | |
| LTM Mar 2026 | $4.58M USD | -40.8% | -33.2% | 5.9% | |
| LTM Mar 2026 | $4.24M USD | -538.4% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $3.89M USD | +220.7% | — | 199.6% |
| LTM Mar 2026 | $684K USD | +142.6% | — | 23.1% | |
| Peer median (excluding CDXS) | — | -22.8% | +0.2% | 47.3% | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Depreciation & Amortization | 5.95M | 10.25M | 9.92M | 4.95M | 5.25M |
| Deferred Income Tax | (2.89M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.59M | 14.53M | 9.97M | 13.09M | 9.62M |
| Change in Working Capital | (7.62M) | 21.57M | (18.22M) | (12.02M) | 6.42M |
| Accounts Receivables | (15.57M) | (3.23M) | 20.25M | 1.25M | 8.51M |
| Inventory | (196K) | (869K) | (656K) | 886K | (19K) |
| Accounts Payables | 268K | 207K | 2.29M | (2.57M) | (1.29M) |
| Other Working Capital | 7.88M | 25.46M | (40.1M) | (11.59M) | (784K) |
| Other Non-Cash Items | (19K) | (1.48M) | 21.93M | 9.85M | 3.31M |
| Operating Cash Flow | (14.27M) | 11.28M | (52.64M) | (49.41M) | (19.38M) |
| Capital Expenditures | (13.83M) | (8.31M) | (4.42M) | (4.31M) | (4.47M) |
| Acquisitions (Net) | 36K | 29K | 751K | 87K | 5K |
| Purchases of Investments | (7.63M) | (5.3M) | (1.19M) | (90.24M) | (57.16M) |
| Sales of Investments | (36K) | (29K) | 440K | 37.47M | 85.13M |
| Other Investing Activities | 36K | 29K | (440K) | 0 | 0 |
| Investing Cash Flow | (21.42M) | (13.58M) | (4.86M) | (56.98M) | 23.5M |
| Debt Repayment | 0 | 0 | 0 | 29.52M | 9.89M |
| Common Stock Issued | 4.97M | 913K | 8.65M | 31.32M | 18.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.21M) | (1.49M) | (485K) | (318K) | 0 |
| Financing Cash Flow | 3.77M | (575K) | 8.17M | 60.52M | 27.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (31.92M) | (2.87M) | (49.33M) | (45.87M) | 32.05M |
| Free Cash Flow | (28.1M) | 2.98M | (57.06M) | (53.72M) | (23.85M) |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.